Skip to Content
Merck

475981

Myosin Light Chain Kinase Inhibitor Peptide 18

The Myosin Light Chain Kinase Inhibitor Peptide 18 controls the biological activity of Myosin Light Chain Kinase. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

Synonym(s):

Myosin Light Chain Kinase Inhibitor Peptide 18, H-RKKYKYRRK-NH2, MLCK Inhibitor Peptide 18, MLCK Inhibitor IV, MLCK Inhibitor Peptide 18, H-RKKYKYRRK-NH2 MLCK Inhibitor IV

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C60H105N23O11
Molecular Weight:
1324.62
NACRES:
NA.77
UNSPSC Code:
12352202
Assay:
≥97% (HPLC)
Form:
lyophilized solid
Quality level:
100
Storage condition:
OK to freeze, desiccated (hygroscopic)

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

assay

≥97% (HPLC)

form

lyophilized solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze, desiccated (hygroscopic)

color

white

solubility

water: 1 mg/mL, DMSO: 5 mg/mL

shipped in

wet ice

storage temp.

−20°C

Quality Level

100

Related Categories

General description

A highly basic, cell-permable, nonapeptide that acts as a selective myosin light chain kinase (MLCK) inhibitor (IC50 = 50 nM). Does not block calmodulin (CaM) or inhibit the kinase activities of Ca2+/calmodulin kinase II (CaMKII) or protein kinase A (PKA). Inhibition is competitive with respect to substrate (Ki = 52 nM). Displays mixed mode inhibition with respect to ATP.
A highly basic, cell-permeable, nonapeptide that acts as a selective Myosin Light Chain Kinase (MLCK) inhibitor (IC50 = 50 nM). The inhibition is competitive with respect to the peptide substrate (Ki = 52 nM) and displays a mixed mode of inhibition with respect to ATP. Does not interfere with kinase activation by calmodulin (CaM), nor does it inhibit the activities of CaMKII and PKA.

Biochem/physiol Actions

Target IC50: 50 nM against MLCK
Cell permeable: yes
Primary Target
Mlck
Product does not compete with ATP.
Reversible: no

Packaging

Packaged under inert gas

Physical form

Supplied as a trifluoroacetate salt.

Preparation Note

Following reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Other Notes

H-Arg-Lys-Lys-Tyr-Lys-Tyr-Arg-Arg-Lys-NH₂
Zolotarevsky, Y., et al. 2002. Gastroenterology123, 163.
Lukas, T.J., et al. 1999. J. Med. Chem.42, 910.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)

Storage Class

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Nicholas J Hunt et al.
The journals of gerontology. Series A, Biological sciences and medical sciences, 75(2), 278-285 (2019-06-15)
Age-related changes in the liver sinusoidal endothelium, particularly the reduction in fenestrations, contribute to insulin resistance in old age. Metformin impacts on the aging process and improves insulin resistance. Therefore, the effects of metformin on the liver sinusoidal endothelium were

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service